Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00262470 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treatment of Orthostatic Intolerance

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 2027 to Dec 2029 Study description expanded, about 62 wordsv26 Show 1 more changeShow less
    • Study description expanded, about 62 words

    See this version in full on ClinicalTrials.gov ↗

  2. Primary and study completion dates: Dec 2025 to Dec 2027v25
  3. Collaborator revisedv24 See this version in full on ClinicalTrials.gov ↗
  4. Re-verified, no change to tracked fieldsv23
  5. Primary and study completion dates: Dec 2022 to Dec 2025v22
Show 20 earlier versionsHide 20 earlier versions
  1. Re-verified, no change to tracked fieldsv21
  2. Primary and study completion dates: Dec 2021 to Dec 2022v20
  3. Re-verified, no change to tracked fieldsv19
  4. Primary completion date: Jan 2018 to Dec 2021 Completion date: Dec 2021v18 Show 1 more changeShow less
    • Completion date: Dec 2021
  5. Re-verified, no change to tracked fieldsv17
  6. Primary completion date: Jan 2016 to Jan 2018 Trial status: Recruiting to Active, Not Recruiting · Site details revisedv16 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
  7. Primary completion date: Jan 2014 to Jan 2016 Interventions: Abdominal binder (Device), Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Baseline (No Drug) (Other)… to Abdominal binder (Device), Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Breathing Device (Device), Clonidine…v15 Show 1 more changeShow less
    • Interventions: Abdominal binder (Device), Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Baseline (No Drug) (Other)… to Abdominal binder (Device), Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Breathing Device (Device), Clonidine…
  8. Lead sponsor: Vanderbilt University to Satish R. Raj Interventions: Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Baseline (No Drug) (Other), Breathing Device (Device)… to Abdominal binder (Device), Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Baseline (No Drug) (Other)… · Publications: 7 to 8 · Study arms: 19 to 20v14 Show 3 more changesShow less
    • Interventions: Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Baseline (No Drug) (Other), Breathing Device (Device)… to Abdominal binder (Device), Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Baseline (No Drug) (Other)…
    • Publications: 7 to 8
    • Study arms: 19 to 20

    See this version in full on ClinicalTrials.gov ↗

  9. Primary completion date: Jan 2013 to Jan 2014 Collaborator revisedv13 Show 1 more changeShow less
    • Collaborator revised

    See this version in full on ClinicalTrials.gov ↗

  10. Re-verified, no change to tracked fieldsv12
  11. Primary completion date: Jan 2011 to Jan 2013v11
  12. 4 versions Re-verified since Jun 2, 2008, no change to tracked fieldsv7-v10
  13. Primary completion date: Jan 2011 Interventions: Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Baseline (No Drug) (Drug), Breathing Device (Procedure)… to Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Baseline (No Drug) (Other), Breathing Device (Device)… · Study arms: 0 to 19v6 Show 2 more changesShow less
    • Interventions: Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Baseline (No Drug) (Drug), Breathing Device (Procedure)… to Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Baseline (No Drug) (Other), Breathing Device (Device)…
    • Study arms: 0 to 19
  14. Interventions: Aprepitant (Drug), Aprepitant and 16 oz of Water (Drug), Atomoxetine (Drug), Baclofen (Drug), Baseline (No Drug) (Drug), Carbidopa (Drug)… to Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Baseline (No Drug) (Drug), Breathing Device (Procedure)… Secondary endpoints: details revised at 5 of 5 entriesv5 Show 1 more changeShow less
    • Secondary endpoints: details revised at 5 of 5 entries
  15. Completion date: Aug 2005 to not stated Secondary endpoints revised (5) · Primary endpoint revisedv4 Show 2 more changesShow less
    • Secondary endpoints revised (5)
    • Primary endpoint revised

    See this version in full on ClinicalTrials.gov ↗

  16. 2 versions Re-verified since Sep 6, 2006, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial is designed to study the effects of various mechanistically unique medications in controlling excessive increases in heart rate with standing and in improving the symptoms of orthostatic intolerance in patients with this disorder.
Trial Details
NCT Number NCT00262470
Lead Sponsor Satish R. Raj
Collaborators: National Center for Advancing Translational Sciences (NCATS)
Conditions Tachycardia, Chronic Orthostatic Intolerance
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov